Melatonin synergistically enhances protective effect of atorvastatin against gentamicin-induced nephrotoxicity in rat kidney

Canadian Journal of Physiology and Pharmacology

Volumn 94, Issue 3, 2015, Pages 265-271

  Mehrzadi, Saeed ^a   Kamrava, Seyed Kamran ^b   Dormanesh, Banafshe ^c   Motevalian, Manijeh ^a   Hosseinzadeh, Azam ^a   Hosseini Tabatabaei, Seyed Mohammad Taghi ^d   Ghaznavi, Habib ^e  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atorvastatin; Gentamicin; Melatonin; Nephrotoxicity; Oxidative stress; Rats

Indexed keywords

ATORVASTATIN; CATALASE; GENTAMICIN; GLUTATHIONE; MALONALDEHYDE; MELATONIN; SUPEROXIDE DISMUTASE; CREATININE; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; UREA;

ARTICLE; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; KIDNEY MASS; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL PROTECTION; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DRUG EFFECTS; KIDNEY; KIDNEY FUNCTION TEST; MALE; METABOLISM; OXIDATIVE STRESS; PROCEDURES; RAT; WISTAR RAT;

ACUTE KIDNEY INJURY; ANIMALS; ATORVASTATIN CALCIUM; CREATININE; DRUG SYNERGISM; GENTAMICINS; GLUTATHIONE; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MALONDIALDEHYDE; MELATONIN; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; UREA;

EID: 84959326217     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2015-0277     Document Type: Article

References (61)

1. Abdel-Raheem, I.T., Abdel-Ghany, A.A., and Mohamed, G.A. 2009. Protective effect of quercetin against gentamicin-induced nephrotoxicity in rats. Biol. Pharm. Bull. 32(1): 61–67. doi:10.1248/bpb.32.61.
2. Absi, E., Ayala, A., Machado, A., and Parrado, J. 2000. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of Complex I of the mitochondrial respiratory chain. J. Pineal Res. 29(1): 40–47. doi:10.1034/j.1600-079X.2000.290106.x.
3. Acuna-Castroviejo, D., Martin, M., Macias, M., Escames, G., Leon, J., Khaldy, H., and Reiter, R.J. 2001. Melatonin, mitochondria, and cellular bioenergetics. J. Pineal Res. 30(2): 65–74. doi:10.1034/j.1600-079X.2001.300201.x.
4. Akakin, D., Kiran, D., Ozkan, N., Ersahin, M., Ozdemir-Kumral, Z.N., Yegen, B., and Sener, G. 2013. Protective effects of melatonin against spinal cord injury induced oxidative damage in rat kidney: A morphological and biochemical study. Acta Histochem. 115(8): 827–834. doi:10.1016/j.acthis.2013.04.005.
5. Allegra, M., Reiter, R., Tan, D.X., Gentile, C., Tesoriere, L., and Livrea, M. 2003. The chemistry of melatonin’s interaction with reactive species. J. Pineal Res. 34(1): 1–10. doi:10.1034/j.1600-079X.2003.02112.x.
6. Arendt, J. 1995. Melatonin and the mammalian pineal gland, London: Chapman Hall.
7. Balakumar, P., Rohilla, A., and Thangathirupathi, A. 2010. Gentamicininduced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol. Res. 62(3): 179–186. doi:10.1016/j.phrs.2010.04.004.
8. Baliga, R., Ueda, N., Walker, P.D., and Shah, S.V. 1999. Oxidant mechanisms in toxic acute renal failure. Drug Metab. Rev. 31(4): 971–997. doi:10.1081/DMR-100101947.
9. Begg, E.J., and Barclay, M.L. 1995. Aminoglycosides–50 years on. Br. J. Clin. Pharmacol. 39(6): 597–603.
10. Cangemi, R., Loffredo, L., Carnevale, R., Perri, L., Patrizi, M.P., Sanguigni, V., et al. 2007. Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur. Heart J. 29(1): 54–62. doi:10.1093/eurheartj/ehm565.
11. Carnevale, R., Pignatelli, P., Di Santo, S., Bartimoccia, S., Sanguigni, V., Napoleone, L., et al. 2010. Atorvastatin inhibits oxidative stress via adiponectinmediated NADPH oxidase down-regulation in hypercholesterolemic patients. Atherosclerosis, 213(1): 225–234. doi:10.1016/j.atherosclerosis.2010.08.056.
12. Cuzzocrea, S., Mazzon, E., Dugo, L., Serraino, I., Di Paola, R., Britti, D., et al. 2002. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur. J. Pharmacol. 450(1): 67–76. doi:10.1016/S0014-2999(02)01749-1.
13. Dam, V.P., Scott, J.L., Ross, A., and Kinobe, R.T. 2012. Inhibition of cystathionine gamma-lyase and the biosynthesis of endogenous hydrogen sulphide ameliorates gentamicin-induced nephrotoxicity. Eur. J. Pharmacol. 685(1): 165–173. doi:10.1016/j.ejphar.2012.04.030.
14. Davignon, J., Jacob, R.F., and Mason, R.P. 2004. The antioxidant effects of statins. Coron. Artery Dis. 15(5): 251–258. doi:10.1097/01.mca.0000131573.31966.34.
15. Dayoub, J.C., Ortiz, F., Lopez, L.C., Venegas, C., del Pino-Zumaquero, A., Roda, O., et al. 2011. Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide. J. Pineal Res. 51(3): 324–330. doi:10.1111/j.1600-079X.2011.00892.x.
16. Fauconneau, B., Tallineau, C., Huguet, F., and Piriou, A. 1995. Gentamicininduced kidney damage and lipid peroxidation in rats. Toxicol. Lett. 76(2): 127–134. doi:10.1016/0378-4274(94)03205-L.
17. Greenwood, J., Steinman, L., and Zamvil, S.S. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6(5): 358–370. doi:10.1038/nri1839.
18. Gurpinar, T., Ekerbicer, N., Uysal, N., Barut, T., Tarakci, F., and Tuglu, M.I. 2010. The histologic evaluation of atorvastatin and melatonin treatment on oxidative stress and apoptosis of diabetic rat pancreas. Kafkas Univ Vet Fak Derg, 16(4): 547–552. doi:10.9775/kvfd.2009.1122.
19. Ha, H., Yu, M.-R., and Kim, K.H. 1999. Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic. Biol. Med. 26(7): 944–950. doi:10.1016/S0891-5849(98)00276-7.
20. Kapur, N.K., and Musunuru, K. 2008. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc. Health Risk Manag. 4(2): 341. doi:10.2147/VHRM.S1653.
21. Karbownik, M., Reiter, R.J., Cabrera, J., and Garcia, J.J. 2001. Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat. Res. 474(1): 87–92. doi:10.1016/S0027-5107(00)00164-0.
22. Kunak, Z.I., Macit, E., Yaren, H., Yaman, H., Cakir, E., Aydin, I., et al. 2012. Protective effects of melatonin and s-methylisothiourea on mechlorethamine induced nephrotoxicity. J. Surg. Res. 175(1): e17–e23. doi:10.1016/j.jss.2011.11.002.
23. Kuo, C.-H., Maita, K., Sleight, S.D., and Hook, J.B. 1983. Lipid peroxidation: a possible mechanism of cephaloridine-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 67(1): 78–88. doi:10.1016/0041-008X(83)90246-6.
24. Kwak, B., Mulhaupt, F., Myit, S., and Mach, F. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6(12): 1399–1402. doi:10.1038/82219.
25. Lee, I.-C., Kim, S.-H., Lee, S.-M., Baek, H.-S., Moon, C., Kim, S.-H., et al. 2012. Melatonin attenuates gentamicin-induced nephrotoxicity and oxidative stress in rats. Arch. Toxicol. 86(10): 1527–1536. doi:10.1007/s00204-012-0849-8.
26. Lopez-Novoa, J.M., Quiros, Y., Vicente, L., Morales, A.I., and Lopez-Hernandez, F.J. 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 79(1): 33–45. doi:10.1038/ki.2010.337.
27. Luchetti, F., Canonico, B., Betti, M., Arcangeletti, M., Pilolli, F., Piroddi, M., et al. 2010. Melatonin signaling and cell protection function. FASEB J. 24(10): 3603–3624. doi:10.1096/fj.10-154450.
28. Mahieu, S., del Carmen Contini, M., Gonzalez, M., and Millen, N. 2009. Melatonin reduces oxidative damage induced by aluminium in rat kidney. Toxicol. Lett. 190(1): 9–15. doi:10.1016/j.toxlet.2009.06.852.
29. Malhotra, S., Sawhney, G., and Pandhi, P. 2004. The therapeutic potential of melatonin: a review of the science. MedGenMed, 6(2).
30. Martin, M., Macias, M., Escames, G., Reiter, R., Agapito, M., Ortiz, G., and Acuna-Castroviejo, D. 2000. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J. Pineal Res. 28(4): 242–248. doi:10.1034/j.1600-079X.2000.280407.x.
31. Martinez-Alfaro, M., Ramirez-Garcia, G., Gutierrez-Granados, S., Alcaraz-Contreras, Y., Gallegos-Corona, M.-A., de Larrea, G.Z.L., and Carabez-Trejo, A. 2013. Melatonin attenuates the effects of sub-acute administration of lead on kidneys in rats without altering the lead-induced reduction in nitric oxide. J. Trace Elem. Med. Biol. 27(4): 364–369. doi:10.1016/j.jtemb.2013.05.003.
32. Mathew, T.H. 1992. Drug-induced renal disease. Med. J. Aust. 156(10): 724–728.
33. Meki, A.-R.M., and Hussein, A.A. 2001. Melatonin reduces oxidative stress induced by ochratoxin A in rat liver and kidney. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 130(3): 305–313. doi:10.1016/S1532-0456(01)00248-4.
34. Montilla, P., Tunez, I., Munoz, M., Lopez, A., and Soria, J. 1997. Hyperlipidemic nephropathy induced by adriamycin: effect of melatonin administration. Nephron, 76(3): 345–350. doi:10.1159/000190202.
35. Mun, K.C., and Suh, S.I. 2000. Effect of melatonin on renal function in cyclosporine nephrotoxicity. Transplant. Proc. 32(7): 1919–1920. doi:10.1016/S0041-1345(00)01492-5.
36. Ohkawa, H., Ohishi, N., and Yagi, K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95(2): 351–358. doi:10.1016/0003-2697(79)90738-3.
37. Ozbek, E., Turkoz, Y., Sahna, E., Ozugurlu, F., Mizrak, B., and Ozbek, M. 2000. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int. 85(6): 742–746. doi:10.1046/j.1464-410x.2000.00531.x.
38. Ozbek, E., Cekmen, M., Ilbey, Y.O., Simsek, A., Polat, E.C., and Somay, A. 2009. Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kB pathways. Ren. Fail. 31(5): 382–392. doi: 10.1080/08860220902835863.
39. Ozler, M., Korkmaz, A., Uysal, B., Simsek, K., Ozkan, C., Topal, T., and Oter, S. 2011. Effects of topical melatonin and vitamin E in a rat ischemic wound model. J. Exp. Integr. Med. 1(2): 123–129. doi:10.5455/jeim.080411.or.006.
40. Pignatelli, P., Carnevale, R., Cangemi, R., Loffredo, L., Sanguigni, V., Stefanutti, C., et al. 2010. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 30(2): 360–367. doi:10.1161/ATVBAHA.109.198622.
41. Priuska, E.M., and Schacht, J. 1995. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem. Pharmacol. 50(11): 1749–1752. doi:10.1016/0006-2952(95)02160-4.
42. Ramirez-Garcia, G., Martinez-Alfaro, M., Gutierrez-Granados, S., Alatorre-Ordaz, A., Griveau, S., and Bedioui, F. 2015. Electrochemical Assessment of Possible Melatonin Effect On Nitric Oxide Production From Kidneys Of Sub-Acute Lead Treated Rats. Electrochim. Acta, 166: 88–92. doi:10.1016/j.electacta.2015.03.063.
43. Reiter, R.J. 1991. Cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 12(2): 151–180. doi:10.1210/edrv-12-2-151.
44. Reiter, R.J., Calvo, J.R., Karbownik, M., Qi, W., and Tan, D.X. 2000. Melatonin and its relation to the immune system and inflammation. Ann. N.Y. Acad. Sci. 917(1): 376–386. doi:10.1111/j.1749-6632.2000.tb05402.x.
45. Reiter, R.J., Tan, D.-x., Mayo, J.C., Sainz, R.M., Leon, J., and Czarnocki, Z. 2003. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol. 50(4): 1129–1146.
46. Reiter, R.J., Tan, D.X., and Maldonado, M.D. 2005. Melatonin as an antioxidant: physiology versus pharmacology. J. Pineal Res. 39(2): 215–216. doi:10.1111/j.1600-079X.2005.00261.x.
47. Rodriguez, C., Mayo, J.C., Sainz, R.M., Antolin, I., Herrera, F., Martin, V., and Reiter, R.J. 2004. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36(1): 1–9. doi:10.1046/j.1600-079X.2003.00092.x.
48. Romero, F., Perez, M., Chavez, M., Parra, G., and Durante, P. 2009. Effect of Uric Acid on Gentamicin-Induced Nephrotoxicity in Rats–Role of Matrix Metalloproteinases 2 and 9. Basic Clin. Pharmacol. Toxicol. 105(6): 416–424. doi:10. 1111/j.1742-7843.2009.00466.x.
49. Sehajpal, J., Kaur, T., Bhatti, R., and Singh, A.P. 2014. Role of progesterone in melatonin-mediated protection against acute kidney injury. J. Surg. Res. 191(2): 441–447. doi:10.1016/j.jss.2014.04.025.
50. Sener, G., Sehirli, A.O., Altunbas, H.Z., Ersoy, Y., Paskaloglu, K., Arbak, S., and Ayanoglu-Dulger, G. 2002. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res. 32(4): 231–236. doi:10.1034/j.1600-079X.2002.01858.x.
51. Sener, G., Sehirli, A.O., Satıroglu, H., Keyer-Uysal, M., and Yegen, B.C. 2002. Melatonin prevents oxidative kidney damage in a rat model of thermal injury. Life Sci. 70(25): 2977–2985. doi:10.1016/S0024-3205(02)01571-0.
52. Shakil, S., Khan, R., Zarrilli, R., and Khan, A.U. 2008. Aminoglycosides versus bacteria–a description of the action, resistance mechanism, and nosocomial battleground. J. Biomed. Sci. 15(1): 5–14. doi:10.1007/s11373-007-9194-y.
53. Shifow, A., Kumar, K., Naidu, M., and Ratnakar, K. 2000. Melatonin, a pineal hormone with antioxidant property, protects against gentamicin-induced nephrotoxicity in rats. Nephron, 85(2): 167–174. doi:10.1159/000045650.
54. Shinomol, G.K., and Muralidhara, 2007. Differential induction of oxidative impairments in brain regions of male mice following subchronic consumption of Khesari dhal (Lathyrus sativus) and detoxified Khesari dhal. Neurotoxicology, 28(4): 798–806. doi:10.1016/j.neuro.2007.03.002.
55. Shishehbor, M.H., Brennan, M.-L., Aviles, R.J., Fu, X., Penn, M.S., Sprecher, D.L., and Hazen, S.L. 2003. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation, 108(4): 426–431. doi: 10.1161/01.CIR.0000080895.05158.8B.
56. Soliman, K.M., Abdul-Hamid, M., and Othman, A.I. 2007. Effect of carnosine on gentamicin-induced nephrotoxicity. Med. Sci. Monit. 13(3): BR73–BR83.
57. Vijayalekshmy, K., Menon, V., and Leelamma, S. 1992. Role of antibiotics in lipid peroxidation. Indian J. Biochem. Biophys. 29(4): 371–374.
58. Wassmann, S., Laufs, U., Muller, K., Konkol, C., Ahlbory, K., Baumer, A.T., et al. 2002. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 22(2): 300–305. doi:10.1161/hq0202.104081.
59. Yanagida, C., Ito, K., Komiya, I., and Horie, T. 2004. Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem. Biol. Interact. 148(3): 139–147. doi:10.1016/j.cbi.2004.05.005.
60. Yazar, E., Elmas, M., Altunok, V., Sivrikaya, A., Oztekin, E., and Birdane, Y.O. 2003. Effects of aminoglycoside antibiotics on renal antioxidants, malondialdehyde levels, and some serum biochemical parameters. Can. J. Vet. Res. 67(3): 239.
61. Yoshida, M. 2003. Potential role of statins in inflammation and atherosclerosis. J. Atheroscler. Thromb. 10(3): 140–144. doi:10.5551/jat.10.140.